市場調査レポート

商品コード

1566200

ナルコレプシー薬の市場規模、シェア、成長分析、疾患タイプ別、治療薬タイプ別、地域別 - 産業予測、2024年～2031年

Narcolepsy Drugs Market Size, Share, Growth Analysis, By Disease Type (Daytime Extreme Sleepiness, Cataplexia), By Therapeutics Type (Central Nervous System Stimulants, Tricyclic Antidepressants), By Region - Industry Forecast 2024-2031

出版日: 2024年10月03日 | 発行: SkyQuest

| ページ情報: 英文 219 Pages | 納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 800,088円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 935,952円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,071,816円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=150.96円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界のナルコレプシー薬の市場規模は、2022年に約34億米ドルと評価され、2023年の37億米ドルから上昇し、予測期間（2024～2031年）のCAGRは9.5%で、2031年には70億米ドルに達すると予測されます。

ナルコレプシー薬市場は、医療を必要とする慢性疾患や急性疾患にかかりやすくなる高齢化など、いくつかの重要な要因によって大幅な成長が見込まれています。ナルコレプシー障害の増加は、ライフスタイルの進化やストレスレベルの高まりによって悪化しており、今後数年間で市場拡大にさらに拍車がかかると予想されます。研究イニシアチブの強化、医療支出の増加、医療インフラの改善が、この成長可能性を裏付けています。さらに、概日リズムの調整、睡眠時間の増加、テレワークの実施といった要因が、中枢性過眠症に関連する症状を効果的に管理できることを示唆しており、ナルコレプシー治療が広く受け入れられることを促しています。しかし、治療や診断に関連する高額な費用や、利用可能な治療法に関する全般的な認識不足といった課題も存在し、市場の進展を妨げる可能性が高いです。不利な償還状況も大きな障害となり、的を絞った研究開発に注力する製薬企業の収益機会に影響を与える可能性があります。このような課題にもかかわらず、米国市場情勢は次の予測期間にわたって安定したCAGRを記録すると予想されます。これは、睡眠関連疾患をますます優先するようになるヘルスケア情勢の進展の中で、治療に対する需要が底堅く推移していることを反映しています。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Jazz Pharmaceuticals plc
Teva Pharmaceutical Industries Ltd.
Bioprojet Pharma SARL
Novartis International AG
Takeda Pharmaceutical Company
Avadel Pharmaceuticals
Mylan N.V.（now part of Viatris）
Aurobindo Pharma
Glenmark Pharmaceuticals
Lupin Pharmaceuticals
Otsuka Pharmaceutical
Biogen
Theravance Biopharma
Ligand Pharmaceuticals
Flamel Technologies（now Avadel Pharmaceuticals）
Biocodex
Sun Pharmaceutical Industries
Cipla Limited
Dr. Reddy's Laboratories
Pfizer Inc.

Product Code: SQMIG35I2087

Global Narcolepsy Drugs Market size was valued at around USD 3.4 billion in 2022 and is expected to rise from USD 3.7 billion in 2023 to reach a value of USD 7 billion by 2031, at a CAGR of 9.5% over the forecast period (2024-2031).

The narcolepsy therapeutics market is poised for substantial growth driven by several key factors, primarily the aging population's increased susceptibility to chronic and acute ailments necessitating medical care. The rise in narcoleptic disorders, exacerbated by evolving lifestyles and heightened stress levels, is expected to further fuel market expansion in the coming years. Enhanced research initiatives, increased healthcare spending, and improved medical infrastructure underscore this growth potential. Additionally, factors such as circadian adjustment, increased sleep, and telework practices suggest that symptoms associated with central hypersomnia can be effectively managed, encouraging a broader acceptance of narcolepsy treatments. However, challenges exist, notably the high costs associated with treatments and diagnostics, coupled with an overarching lack of awareness regarding available therapies, which are likely to hinder market progress. The unfavorable reimbursement landscape also poses significant obstacles, potentially impacting revenue opportunities for pharmaceutical companies focused on targeted research and development. Despite these challenges, the US narcolepsy drugs market is expected to experience a steady compound annual growth rate (CAGR) over the next forecast period, reflecting a resilient demand for treatments amid an evolving healthcare landscape that increasingly prioritizes sleep-related disorders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Narcolepsy Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Narcolepsy Drugs Market Segmental Analysis

Global Narcolepsy Drugs Market is segmented by Disease Type, Therapeutics Type, and region. Based on Disease Type, the market is segmented into Daytime Extreme Sleepiness, Cataplexia, and Other Disease Type. Based on Therapeutics Type, the market is segmented into Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, and Other Therapeutic Type. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Narcolepsy Drugs Market

Growing awareness surrounding narcolepsy treatment plays a crucial role in driving the Global Narcolepsy Drugs market from 2023 to 2030. As more patients and healthcare providers recognize the impact of the condition on quality of life, the demand for effective treatments is surging. Notably, the preference for modafinil, which is known for its favorable safety profile compared to traditional stimulants, is further contributing to this trend. This increased focus on appropriate therapeutic options not only enhances patient outcomes but also fosters market growth, as effective therapies become more widely adopted, driving sales and innovation within the narcolepsy drug sector.

Restraints in the Global Narcolepsy Drugs Market

A significant market restraint for the global narcolepsy drugs market is the frequent misdiagnosis of narcolepsy symptoms, which are often confused with various mental and neurological disorders. This lack of awareness leads to inappropriate prescriptions of antiepileptics and psychiatric medications, particularly in children and adolescents, potentially causing adverse health effects. The resulting hesitation from healthcare providers to accurately diagnose and treat narcolepsy can hinder market growth, as patients may not receive the necessary therapy for their condition. Additionally, this confusion can create mistrust among patients towards seeking effective treatments, further limiting market opportunities for narcolepsy drug manufacturers.

Market Trends of the Global Narcolepsy Drugs Market

The global narcolepsy drugs market is poised for significant growth, fueled by the rising prevalence of narcolepsy and associated sleep disorders across diverse demographics. Increasing incidences of obesity-related narcolepsy variants further bolster market expansion, highlighting the pressing need for effective therapeutic solutions. Government initiatives aimed at enhancing awareness and understanding of narcolepsy are anticipated to drive demand for treatment options. Moreover, hospitals are emerging as the primary end-use sector, capturing the largest share of the market as more patients seek specialized care. Overall, this confluence of factors positions the narcolepsy drugs market for robust growth in the coming years.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Regulatory Analysis
Case Study Analysis
Clinical Trials

Narcolepsy Drugs Market, By Disease Type

Market Overview
Daytime Extreme Sleepiness
Cataplexia
Other Disease Type

Narcolepsy Drugs Market, By Therapeutics Type

Market Overview
Central Nervous System Stimulants
Tricyclic Antidepressants
Sodium Oxybate
Selective Serotonin Reuptake Inhibitor
Other Therapeutic Type

Narcolepsy Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Jazz Pharmaceuticals plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioprojet Pharma SARL
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Avadel Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (now part of Viatris)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glenmark Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Theravance Biopharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ligand Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Flamel Technologies (now Avadel Pharmaceuticals)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocodex
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

ナルコレプシー薬の市場規模、シェア、成長分析、疾患タイプ別、治療薬タイプ別、地域別 - 産業予測、2024年～2031年

Narcolepsy Drugs Market Size, Share, Growth Analysis, By Disease Type (Daytime Extreme Sleepiness, Cataplexia), By Therapeutics Type (Central Nervous System Stimulants, Tricyclic Antidepressants), By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

ナルコレプシー薬市場：疾患タイプ別

ナルコレプシー薬市場：治療薬タイプ別

ナルコレプシー薬市場規模：地域別